July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Derivation of RPE cells from human embryonic stem cells: The journey from basic research to clinical application
Author Affiliations & Notes
  • Eyal Banin
    Ophthalmology, Hadassah-Hebrew Univ Med Ctr, Jerusalem, Israel
  • Footnotes
    Commercial Relationships   Eyal Banin, CellCure Neurosciences (C), CellCure Neurosciences (P)
  • Footnotes
    Support  Israeli Science Foundation, GT Foundation, Yedidut Research Fund, CellCure Neurosciences
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2582. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eyal Banin; Derivation of RPE cells from human embryonic stem cells: The journey from basic research to clinical application. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2582.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : In 2003 we set out to explore the possibility of using human embryonic stem cells (hESCs) as a platform for the treatment of retinal disease. In this presentation I will describe our journey from the development of a directed differentiation protocol that allows efficient derivation of retinal pigment epithelium (RPE) cells from hESCs "in the culture dish" to the application of this technology in an ongoing phase I/IIa trial in patients with advanced dry age-related macular degeneration. Milestones along the way that are relevant to the process of drug / treatment development include in-vitro characterization of cell differentiation, testing in animal models, the transition from basic research to the translational phase that included the production of clinical grade hESC-derived RPE cells under xeno-free conditions, rigorous testing to ensure safety and efficacy of these cells, designing a phase I/IIa clinical trial, obtaining FDA approval and finally launching of the clinical trial. Lessons learned along the way will be shared.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×